Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | GRM5 | P41594 | 4/20 | 0.33 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.31 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.31 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.31 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.31 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1920419 | 1.00 | THRB (0.36) | THRBMEN1KMT2AGRM5GRM1 | |
| SCHEMBL1920420 | 1.00 | THRB (0.36) | THRBMEN1KMT2AGRM5GRM1 | |
| SCHEMBL1031355 | 0.95 | THRB (0.43) | THRBMEN1KMT2AGRM5GRM1 | |
| SCHEMBL1031354 | 0.95 | THRB (0.43) | THRBMEN1KMT2AGRM5GRM1 | |
| SCHEMBL28776609 | 0.95 | THRB (0.43) | THRBMEN1KMT2AGRM5GRM1 | |
| SCHEMBL1031356 | 0.95 | THRB (0.43) | THRBMEN1KMT2AGRM5GRM1 | |
| Heptane SCHEMBL28774909 | 0.80 | NAAA (0.40) | — | |
| SCHEMBL27769894 | 0.75 | TSHR (0.38) | GRM5GRM1LMNACYP3A4GABRA1 | |
| SCHEMBL28933940 | 0.74 | TSHR (0.33) | GRM5GRM1LMNACYP3A4GABRA1 | |
| Sulfuric Acid SCHEMBL3390334 | 0.73 | THRB (0.62) | THRBMEN1KMT2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119023991-A | Imaging system and method for speed field detection | 天津大学 | 2024-11-26 | — | — | CN | claimed |
| US-20160206579-A1 | TAURINE OR TAURINE-LIKE SUBSTANCES FOR THE PREVENTION AND TREATMENT OF A DISEASE ASSOCIATED WITH RETINAL GANGLION CELL DEGENERATION | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2016-07-21 | — | — | US | claimed |
| US-20120027723-A1 | TAURINE OR TAURINE-LIKE SUBSTANCES FOR THE PREVENTION AND TREATMENT OF A DISEASE ASSOCIATED WITH RETINAL GANGLION CELL DEGENERATION | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2012-02-02 | — | — | US | claimed |
| EP-2393490-A1 | TAURINE OR TAURINE-LIKE SUBSTANCES FOR THE PREVENTION AND TREATMENT OF A DISEASE ASSOCIATED WITH RETINAL GANGLION CELL DEGENERATION | INSERM - Institut National de la Santé et de la Recherche Médicale (FR) | 2011-12-14 | — | — | EP | claimed |
| US-20110172171-A1 | TAURINE OR TAURINE-LIKE SUBSTANCES FOR THE PREVENTION OF BRAIN OEDEMA | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2011-07-14 | — | — | US | claimed |
| EP-2326321-A1 | TAURINE OR TAURINE-LIKE SUBSTANCES FOR THE PREVENTION OF BRAIN OEDEMA | Inserm (Institut National de la Santé et de la Recherche Scientifique) (FR) | 2011-06-01 | — | — | EP | claimed |
| WO-2010089355-A1 | TAURINE OR TAURINE-LIKE SUBSTANCES FOR THE PREVENTION AND TREATMENT OF A DISEASE ASSOCIATED WITH RETINAL GANGLION CELL DEGENERATION | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2010-08-12 | — | — | WO | claimed |
| US-20100184707-A1 | ANTICONVULSIVE PHARMACEUTICAL COMPOSITIONS | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2010-07-22 | — | — | US | claimed |
| WO-2010029021-A1 | TAURINE OR TAURINE-LIKE SUBSTANCES FOR THE PREVENTION OF BRAIN OEDEMA | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2010-03-18 | — | — | WO | claimed |
| EP-2163246-A1 | Taurine or taurine-like substances for the prevention of the irreversible visual effects of vigabatrin | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2010-03-17 | — | — | EP | claimed |
| EP-2011491-A1 | Anticonvulsive pharmaceutical compositions | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2009-01-07 | — | — | EP | claimed |
| US-20260107008-A1 | AFFINE MOTION BASED PREDICTION IN VIDEO CODING | MEDIATEK INC (TW) | 2026-04-16 | — | — | US | disclosed |
| EP-4595776-A1 | NUTRITIONAL COMPOSITION FOR CANCER PATIENTS AND ELDERLY SUBJECTS | Pasqualetti, Giuseppe (IT) | 2025-08-06 | — | — | EP | disclosed |
| US-12282749-B2 | Configurable MAC pipelines for finite-impulse-response filtering, and methods of operating same | ANALOG DEVICES, INC. (US) | 2025-04-22 | — | — | US | disclosed |
| US-20250028051-A1 | TIME-OF-FLIGHT SENSOR AND ELECTRONIC DEVICE | SONY SEMICONDUCTOR SOLUTIONS CORPORATION (JP) | 2025-01-23 | — | — | US | disclosed |
| WO-2010089355-A1 | TAURINE OR TAURINE-LIKE SUBSTANCES FOR THE PREVENTION AND TREATMENT OF A DISEASE ASSOCIATED WITH RETINAL GANGLION CELL DEGENERATION | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2010-08-12 | — | — | WO | disclosed |
| US-20100184707-A1 | ANTICONVULSIVE PHARMACEUTICAL COMPOSITIONS | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2010-07-22 | — | — | US | disclosed |
| WO-2010029021-A1 | TAURINE OR TAURINE-LIKE SUBSTANCES FOR THE PREVENTION OF BRAIN OEDEMA | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2010-03-18 | — | — | WO | disclosed |
| EP-2163246-A1 | Taurine or taurine-like substances for the prevention of the irreversible visual effects of vigabatrin | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2010-03-17 | — | — | EP | disclosed |
| EP-2011491-A1 | Anticonvulsive pharmaceutical compositions | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2009-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260107008-A1 | AFFINE MOTION BASED PREDICTION IN VIDEO CODING | CCL11, MMP26, MYO3A | THRB 4156/4885MEN1 1570/4885KMT2A 866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.